The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease

Kidney International

Volumn 82, Issue 6, 2012, Pages 693-700

  Bosworth, Cortney R ^a   Levin, Gregory ^a   Robinson Cohen, Cassianne ^a   Hoofnagle, Andrew N ^a   Ruzinski, John ^a   Young, Bessie ^a,b   Schwartz, Stephen M ^a   Himmelfarb, Jonathan ^a   Kestenbaum, Bryan ^a   De Boer, Ian H ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

chronic kidney disease; mineral metabolism; vitamin D

Indexed keywords

24,25 DIHYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; BICARBONATE; CALCITRIOL; PARATHYROID HORMONE;

ADULT; AFRICAN AMERICAN; ALBUMINURIA; ARTICLE; BICARBONATE BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SECONDARY HYPERPARATHYROIDISM; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM;

EID: 84865705280     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.193     Document Type: Article

References (42)

1. Fraser DR, Kodicek E. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature 1970; 228: 764-766.
2. Gray R, Boyle I, DeLuca HF. Vitamin D metabolism: the role of kidney tissue. Science 1971; 172: 1232-1234.
3. Myrtle JF, Haussler MR, Norman AW. Evidence for the biologically active form of cholecalciferol in the intestine. J Biol Chem 1970; 245: 1190-1196.
4. Kodicek E, Lawson DE, Wilson PW. Biological activity of a polar metabolite of vitamin D. Nature 1970; 228: 763-764.
5. Blunt JW, Tanaka Y, DeLuca HF. Biological activity of 25-hydroxycholecalciferol, a metabolite of vitamin D3. Proc Natl Acad Sci USA 1968; 61: 1503-1506.
6. Brickman AS, Sherrard DJ, Jowsey J et al. 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy. Arch Intern Med 1974; 134: 883-888.
7. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25- dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143.
8. Group KDIGOKC-MW. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009: S1-S130.
9. Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 2011; 1814: 186-199.
10. Shinki T, Jin CH, Nishimura A et al. Parathyroid hormone inhibits 25-hydroxyvitamin D3-24-hydroxylase mRNA expression stimulated by 1 alpha,25-dihydroxyvitamin D3 in rat kidney but not in intestine. J Biol Chem 1992; 267: 13757-13762.
11. Akeno N, Saikatsu S, Kawane T et al. Mouse vitamin D-24-hydroxylase: molecular cloning, tissue distribution, and transcriptional regulation by 1alpha,25-dihydroxyvitamin D3. Endocrinology 1997; 138: 2233-2240.
12. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
13. Leeuwenkamp O, van der Wiel H, Lips P et al. Human pharmacokinetics of orally administered (24 R)-hydroxycalcidiol. Eur J Clin Chem Clin Biochem 1993; 31: 419-426.
14. Kalantar-Zadeh K, Shah A, Duong U et al. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl 2010: S10-S21.
15. Gray RW, Weber HP, Dominguez JH et al. The metabolism of vitamin D3 and 25-hydroxyvitamin D3 in normal and anephric humans. J Clin Endocrinol Metab 1974; 39: 1045-1056.
16. Granata S, Zaza G, Simone S et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 2009; 10: 388.
17. Michaud J, Nolin TD, Naud J et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci 2008; 108: 157-163.
18. Sun DF, Zheng Z, Tummala P et al. Chronic uremia attenuates growth hormone-induced signal transduction in skeletal muscle. J Am Soc Nephrol 2004; 15: 2630-2636.
19. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97: 105-114.
20. Helvig CF, Cuerrier D, Hosfield CM et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int 2010; 78: 463-472.
21. Zehnder D, Quinkler M, Eardley KS et al. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 2008; 74: 1343-1353.
22. Takemoto F, Shinki T, Yokoyama K et al. Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats. Kidney Int 2003; 64: 414-420.
23. Da B, David V, Alshayeb HM et al. Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites. Kidney Int 2012 (in press).
24. Zerwekh JE, McPhaul JJ, Parker TF et al. Extra-renal production of 24,25-dihydroxyvitamin D in chronic renal failure during 25 hydroxyvitamin D3 therapy. Kidney Int 1983; 23: 401-406.
25. Ishimura E, Nishizawa Y, Inaba M et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999; 55: 1019-1027.
26. Horst RL, Littledike ET, Gray RW et al. Impaired 24,25-dihydroxyvitamin D production in anephric human and pig. J Clin Invest 1981; 67: 274-280.
27. Weisman Y, Eisenberg Z, Leib L et al. Serum concentrations of 24,25-dihydroxy vitamin D in different degrees of chronic renal failure. Br Med J 1980; 281: 712-713.
28. Koenig KG, Lindberg JS, Zerwekh JE et al. Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. Kidney Int 1992; 41: 161-165.
29. Strathmann FG, Laha TJ, Hoofnagle AN. Quantification of 1\{alpha\},25-dihydroxy vitamin d by immunoextraction and l. Clin Chem 2011.
30. Kawashima H, Torikai S, Kurokawa K. Localization of 25-hydroxyvitamin D3 1 alpha-hydroxylase and 24-hydroxylase along the rat nephron. Proc Natl Acad Sci USA 1981; 78: 1199-1203.
31. Brunette MG, Chan M, Ferriere C et al. Site of 1,25(OH)2 vitamin D3 synthesis in the kidney. Nature 1978; 276: 287-289.
32. Kanwar YS, Sun L, Xie P et al. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 2011; 6: 395-423.
33. Patel S, Barron JL, Mirzazedeh M et al. Changes in bone mineral parameters, vitamin D metabolites, and PTH measurements with varying chronic kidney disease stages. J Bone Miner Metab 2011; 29: 71-79.
34. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
35. Carter JL, O'Riordan SE, Eaglestone GL et al. Bone mineral metabolism and its relationship to kidney disease in a residential care home population: a cross-sectional study. Nephrol Dial Transplant 2008; 23: 3554-3565.
36. Craver L, Marco MP, Mart́nez I et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007; 22: 1171-1176.
37. Hoofnagle AN, Laha TJ, Donaldson TF. A rubber transfer gasket to improve the throughput of liquid-liquid extraction in 96-well plates: application to vitamin D testing. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1639-1642.
38. Association AD. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33(Suppl 1): S11-S61.
39. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
40. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
41. Barlow WE, Ichikawa L, Rosner D et al. Analysis of case-cohort designs. J Clin Epidemiol 1999; 52: 1165-1172.
42. Mark S, Katki H. Specifying and implementing nonparametric and semiparametric survival estimators in two-stage (nested) cohort studies with missing case data. J Am Stat Assoc 2006; 101: 460-471.